# Who does Vertex Pharmaceuticals Incorporated pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/vertex-pharmaceuticals · Facet: suppliers · Updated: 2026-09-11T13:41:14.75722+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Vertex Pharmaceuticals Incorporated's confirmed suppliers/cost counterparties include Moderna plus 2 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 3 cost edges, backed by 4 dated sources, 1 of them primary filings (as of 2026-09-11).

### 알파인 이뮨 사이언시스 (high)
- metric: Amount $5B · 2024 acquisition · Total cash paid to acquire Alpine Immune Sciences
- note: Vertex acquired all outstanding shares of Alpine Immune Sciences in 2024, gaining the IgA nephropathy candidate povetacicept. The disclosed total cash paid was USD 4.9575 billion.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-13) https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm: "Total cash consideration paid to Alpine 4,957.5."
- [confirms] BioSpectator (KO, news, published 2024-04-11) https://m.biospectator.com/view/news_view.php?varAtcId=21647: "Vertex Pharmaceuticals will acquire Alpine Immune Sciences for USD 4.9 billion."

### 모더나 (high)  → /moderna.md
- metric: Contract value $270M · agreement life · Maximum development and regulatory milestones payable to Moderna, excluding royalties on net sales
- note: Vertex maintains a license and collaboration agreement with Moderna to develop mRNA therapeutics for cystic fibrosis. Moderna is eligible for up to USD 270 million in development and regulatory milestones plus royalties on future net sales.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-13) https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm: "Moderna is eligible to receive up to $270.0 million in development and regulatory milestones."

### CRISPR 테라퓨틱스 AG (high)
- metric: Amount $200M · 2024-01 · Milestone Vertex paid to CRISPR Therapeutics following FDA approval of CASGEVY
- note: Vertex co-develops and commercializes CASGEVY with CRISPR Therapeutics. It paid CRISPR a USD 200 million milestone in January 2024 following FDA approval and continues to allocate CASGEVY net profit or loss under the agreement.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-13) https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm: "We made a $200.0 million milestone payment to CRISPR in January 2024."
- [confirms] CRISPR Therapeutics (EN, ir, published 2023-12-08) https://ir.crisprtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-us-fda-approval/: "Vertex will make a $200 million milestone payment to CRISPR."
- [mentions] The Motley Fool (EN, analysis, published 2021-04-20) https://www.fool.com/investing/2021/04/20/vertex-pharmaceuticals-raises-bet-on-crispr-therap/: "CRISPR Therapeutics could receive a $200 million milestone payment."

### 론자 (high)
- note: Lonza is Vertex's strategic manufacturing partner for type 1 diabetes cell therapy candidates. The companies collaborate on process development and scale-up and co-invest in a dedicated facility, but Vertex's payments are not disclosed.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-13) https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm: "We have a strategic agreement with Lonza to support the manufacture of T1D cell therapy product candidates."
- [confirms] Lonza (EN, ir, published 2023-06-26) https://www.lonza.com/news/2023-06-26-13-30: "Vertex and Lonza will partner in process development and scale-up for manufacturing."

Reverse side: https://valuechain.wiki/vertex-pharmaceuticals/customers.md · Ripple: https://valuechain.wiki/vertex-pharmaceuticals/ripple.md

---
Full node: https://valuechain.wiki/vertex-pharmaceuticals.md · JSON: https://valuechain.wiki/vertex-pharmaceuticals.json